Fate develops programmed cellular immunotherapies for the treatment of metastatic cancer, traumatic injury and degenerative diseases...
Read moreFate develops programmed cellular immunotherapies for the treatment of metastatic cancer, traumatic injury and degenerative diseases...
Read moreAnnual Revenue
$69M
Fate Therapeutics's revenue is the ranked 5th among it's top 10 competitors. The top 10 competitors average 13.8B. Over the last four quarters, Fate Therapeutics's revenue has decreased by 12.2%. Specifically, in Q3 2022's revenue was $15M; in Q2 2022, it was $18.5M; in Q1 2022, it was $18.4M; in Q4 2021, Fate Therapeutics's revenue was $17.1M.